PAQ Therapeutics is a clinical-stage biotechnology company developing best- and first-in-class KRAS degraders for lethal cancers lacking effective treatment options.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/02/25 | $39,000,000 | Series B |
Bayland Capital BioTrack Capital Johnson & Johnson Development Corporation (JJDC) LAV Fund MRL Ventures Fund Sherpa Health Partners | undisclosed |
